Bydureon

DRUG6 trials

Sponsors

Phoenix VA Health Care System, Baylor Research Institute, AstraZeneca, Karolinska Institutet, Ingrid Jazet

Conditions

AtherosclerosisChronic Kidney DiseaseDiabetesLeft Ventricular Diastolic DysfunctionObesityRestenosisType 2 DiabetesType 2 Diabetes Mellitus

Phase 3

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

CompletedNCT02251431

Baylor Research InstituteChronic Kidney Disease, Left Ventricular Diastolic Dysfunction, Type 2 Diabetes Mellitus

Start: 2015-11-01End: 2019-12-01Updated: 2026-02-19

Phase 4

Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

Phoenix VA Health Care SystemType 2 Diabetes

Start: 2014-06-30End: 2019-09-30Target: 148Updated: 2018-06-14

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

CompletedNCT02288273

AstraZenecaType 2 Diabetes

Start: 2014-12-31End: 2015-08-31Updated: 2017-01-27

A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

CompletedNCT02533453

AstraZenecaType 2 Diabetes Mellitus

Start: 2016-01-28End: 2016-12-07Updated: 2019-05-31

Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects

CompletedNCT02621489

Karolinska InstitutetAtherosclerosis, Diabetes, Restenosis

Start: 2015-12-31End: 2022-10-31Updated: 2023-04-20

Exenatide and Brown Adipose Tissue

Ingrid JazetObesity

Start: 2016-08-31Target: 24Updated: 2016-12-26

Related Papers

Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study

Cardiovascular Diabetology2023-12-08

Twelve weeks of exenatide treatment increases [<sup>18</sup>F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males.

2020-01-2342 citations